In addition, EP300- and CREBBP-ZNF384 fusions resulted in loss of histone lysine acetyltransferase activity with concomitant global reduction of histone acetylation and increased sensitivity of leukemia cells to histone deacetylase inhibitors (6). Here, CREBBP is linked to leukemia.